Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 77

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 77
---
 agreements with leading academic institutions and other biotechnology 
 companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability of clinical    
 success, including programs beyond our target franchise areas and current technology footprint.                                             |

| 48 |

| ● | Invest                                                                                                                              
 in our HDAC platform technology and maximize its utility across cancer therapies. We are initially applying the platform to develop 
 drugs for cancer radiation sensitization, normal tissue radiation protection and post radiation immune stimulation. Based on the    
 data we have obtained thus far, these drugs are immune regulatory. We intend to invest to develop other properties of our platform  
 technology, as well.                                                                                                                |
| ● | Enter                                                                                                                               
 into collaborations to realize the full potential of our platform. The breadth of our HDAC technology platform enables other        
 therapeutic applications, including radiation sensitization and immune therapy. We intend to seek collaborations centered on our    
 platform to maximize applications for cancer treatment.                                                                             |
| ● | Establish                                                                                                                           
 Shuttle Diagnostics, Inc. as a subsidiary of SHPH to advance development of the predictive biomarker (PC-RAD Test) and the PSMA     
 ligand (PSMA-B) to advance prostate cancer treatment.                                                                               |

Radiation Therapy

Radiation Oncologists use Radiation Therapy (RT) to treat cancers that cannot be completely removed by surgery but have not yet spread to distant sites within the body. RT has been a mainstay for the treatment of cancer malignancies for more than half a century. The combination treatment of radiation therapy and chemotherapy has involved the use of cytotoxic drugs, targeted biologic agents and targeted external beam radiation to increase the destruction of tumor cells and cure or delay cancer progression. The low number of drugs and biologic agents under investigation as radiation sensitizing agents highlights an unmet need for new approaches and agents that provide greater effectiveness, increased quality and better tolerability for patients.

Currently, “chemo-radiation” treatments are established in cancers of the head and neck, esophagus, lung, stomach, breast, brain, pancreas, rectum and uterine cervix. The ideal radiation sensitizer would reach the tumor in adequate concentrations and act selectively in the tumor, as compared to surrounding normal tissues. It would have predictable pharmacokinetics for timing with radiation therapy and could be administered with every radiation treatment approach. The ideal radiation sensitizer would have minimal toxicity or manageable enhancement of radiation toxicity.

The U.S. market for radiation sensitizing agents is experiencing dynamic growth through development